Genmab — Maj 2020
-
JNJ-61186372, an EGFR-cMet bispecific antibody, in EGFR Exon 20 insertion-driven advanced non-small cell lung cancer (NSCLC) https://www.abstractsonline.com/pp8/#!/9045/presentation/5116
-
JNJ-61186372, an Fc enhanced EGFR/cMet bispecific antibody, mediates EGFR and cMet downmodulation and therapeutic efficacy preclinically through monocyte / macrophage mediated trogocytosis https://www.abstractsonline.com/pp8/#!/9045/presentation/7722
-
JNJ-67571244: A novel anti-CD33 C2 domain binding bispecific antibody with potent T cell redirection activity https://www.abstractsonline.com/pp8/#!/9045/presentation/7733
-
a few abstracts on BMS-986253
at ASCO (talking about something where i think there is not much to look forward to lol) -
@Mohty_EBMT
presented an argument FOR the integration of anti-CD38 antibodies into induction therapies. https://twitter.com/MM_Hub/status/1261257388159635456 -
Educational theme | Monoclonal antibodies for the treatment of multiple myeloma https://multiplemyelomahub.com/medical-information/educational-theme-monoclonal-antibodies-for-the-treatment-of-multiple-myeloma
-
-
https://www.fiercebiotech.com/biotech/what-pandemic-adc-s-233m-listing-biotech-ipos-keep-rolling this has a bit more on Cami
-
Fandt nedenståen i securities filingen fra ADC - ikke uinteressant vist, der blev talt om det herinde for nylig (GENs mulighed for at forhandle de 25%). https://www.sec.gov/Archives/edgar/data/1771910/000114036120009738/nt10009045x3_f1.htm
-
"Risks Related to Our Relationship with Third Parties / Our rights to Cami are subject to our collaboration and license agreement with Genmab, and there can be no assurance that we will maintain the rights to develop or commercialize Cami. / Our collaboration and license agreement with Genmab requires a divestment of Cami, in which Genmab has a 25% interest, following 60 days, and no later than 65 days, after the database lock for the Phase 1/2 clinical trial, which occurred on April 2, 2020."
-
"See “Business—License and Collaboration Agreements—Genmab Collaboration and License Agreement.” The agreement sets out a defined process to facilitate the divestment of Cami by licensing the rights thereto to a third party, subject to Genmab’s right of first opportunity to negotiate to acquire Cami in full. This process includes the opportunity for both parties to bid for the license rights alongside third parties."
-
"Both parties are required to use commercially reasonable efforts to complete and maximize the value obtained in this process. Therefore, our rights to Cami are subject to our collaboration and license agreement with Genmab, and there can be no assurance that we will apply for regulatory approval of or commercialize Cami."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind